Igor Zydlewski

Igor Zydlewski

Auto-generated profile, based on publicly available information

Igor Zydlewski

Medical University of Warsaw, Żwirki i Wigury 61, 02-091 Warsaw, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MSMarcin SęKulski
Marcin SęKulski
MMMartyna Mrozek
Martyna Mrozek
IZIgor Zydlewski
Igor Zydlewski
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
MPMartyna Pacanowska-Trawnicka
Martyna Pacanowska-Trawnicka
PJPaweł Jakubiec
Paweł Jakubiec
Aim: To summarize current clinical knowledge on the manifestations, organ-specific complications, and medical management of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic syndrome). Methods: A review of peer-reviewed clinical cohorts, registry evaluations and consensus reports published between 2020 and 2026 was conducted using PubMed, MEDLINE, and Google Scholar. Studies addressing clinical phenotypes, organ manifestations, and treatment responses were analyzed. Results: VEXAS syndrome is an adult-onset autoinflammatory disorder caused by somatic mutations in the UBA1 gene within hematopoietic stem cells. It predominantly affects older males and is characterized by systemic inflammation alongside progressive hematologic abnormalities. High-dose oral glucocorticoids reliably achieve rapid flare control - however, steroid dependency is nearly universal and long-term toxicity is substantial. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) show minimal efficacy. Janus kinase (JAK) inhibitors have emerged as the most consistent targeted medical therapy for controlling inflammatory symptoms and reducing steroid exposure. Interleukin-1 (IL-1) and interleukin-6 (IL-6) inhibitors provide partial benefit but carry risks of secondary loss of response, severe injection-site reactions, or serious infections. For patients with high-risk myelodysplastic syndrome (MDS) features or severe cytopenias, the hypomethylating agent azacitidine reduces clonal burden and improves blood counts. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for eligible candidates. Long-term therapeutic anticoagulation is indicated for unprovoked thrombosis, and routine antimicrobial prophylaxis is essential. Conclusion: Managing VEXAS syndrome requires an integrated strategy: rapid suppression of acute inflammation with corticosteroids, maintenance with targeted therapy (ruxolitinib), clonal suppression (azacitidine or allo-HSCT) for marrow failure and aggressive infection prophylaxis.

30 May 2026 in Quality in Sport
Verified
Journal Article
Open access
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
AJAleksandra Jakimowicz
Aleksandra Jakimowicz
ZKZuzanna Zofia Kamińska
Zuzanna Zofia Kamińska
AMAleksandra Malcher
Aleksandra Malcher
MMMartyna Mrozek
Martyna Mrozek
IZIgor Zydlewski
Igor Zydlewski
Introduction: Facing the increasing number of people suffering from obesity, overweight and weight-related comorbidities, the development of medications that support weight loss is crucial. The currently available therapies based on glucagon-like peptide receptor 1 agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 RAs allow for weight loss of 8-21% [1]. However, a significant factor reducing treatment adherence is subcutaneous route of administation by injection, as well ass - in the case of oral semaglutide – restrictive dosing requirements: the drug need to be taken at least 30 minutes before the first meal, beverage, or other oral medication in the morning and with no more than 120 ml of plain water [2]. Aim of the study: The purpose of this study is to review the safety and tolerance of orforglipron and to compare it with oral semaglutide based on ACHIEVE-3 clinical trail. Material and Methods: Review and analysis of randomised clinical trials available on PubMed. We excluded phase 1 trials in analysis of patients with obesity without diabetes mellitus and patients with DM2. Notably, main clinical trials focusing on orforglipron were funded or supported by Eli Lilly and Company. Conclusions: Orforglipron is definitely promising as a small-molecule GLP-1 receptor agonist. The therapy is effective in body weight reduction and results in a significant, dose-dependent reduction in HbA1c levels. With significant effect on weight loss, cardiometabolic parameters and improvement in glycemic profile, it can be used in combination with a reduced-calorie diet and increased physical activity in adults, as a weight-loss therapy or in patient with type 2 diabetes. However, all of the studies published so far on the innovative molecule of orforglipron were based on limited number of patients, therefore long-term safety, tolerance in a larger population and general long-term impact of orforglipron on health needs extensive studies.

16 May 2026 in Quality in Sport
Verified
Journal Article
Open access
AZAgnieszka Zielińska
Agnieszka Zielińska
ZKZuzanna Zofia Kamińska
Zuzanna Zofia Kamińska
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
MMMartyna Mrozek
Martyna Mrozek
IZIgor Zydlewski
Igor Zydlewski
AMAleksandra Malcher
Aleksandra Malcher
Background. Congenital heart diseases (CHDs) are the most common congenital anomalies and a leading cause of infant morbidity and mortality. Although genetic factors play an important role, many cases remain unexplained, highlighting the contribution of maternal and environmental exposures. Aim. This review aims to provide a comprehensive and up-to-date synthesis of non-genetic maternal risk factors associated with CHDs in offspring. Material and methods. A literature review was conducted using PubMed, NCBI and Google Scholar, including studies published between 2010 and 2025. Systematic reviews, meta-analyses, cohort and case-control studies evaluating maternal and environmental exposures were analyzed. Results. Evidence indicates that maternal diabetes and obesity are key risk factors, with clear dose-response relationships. Additional contributors include smoking (active and passive), alcohol consumption, infections, fever, psychological stress and environmental pollutants. Protective effects of folic acid and multivitamin supplementation were also observed. Interaction effects between environmental exposures and parental behaviors further increase CHD risk. Conclusions. CHD etiology is multifactorial, involving modifiable maternal and environmental factors. Identification and reduction of these exposures, particularly during early pregnancy, are essential for prevention. Further prospective and mechanistic studies are needed to clarify causal pathways and improve risk reduction strategies.

14 March 2025 in Quality in Sport
Verified
Journal Article
Open access
MPMartyna Pacanowska
Martyna Pacanowska
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
IZIgor Zydlewski
Igor Zydlewski
MMMartyna Mrozek
Martyna Mrozek
ANAlicja Nowik
Alicja Nowik
PJPaweł Jakubiec
Paweł Jakubiec
Introduction: Creatine is a naturally occurring compound that plays a primary role in energy metabolism, particularly within muscle cells. Its main sites of synthesis include the liver, kidneys, and pancreas [1,2]. This compound is crucial for muscle recovery following exercise. Creatine's ability to rapidly replenish ATP stores reduces fatigue and muscle soreness, thereby accelerating the recovery process. By increasing the availability of phosphocreatine in muscle cells, creatine significantly enhances the capacity to perform both short-duration and high-intensity exercises [4,8]. This allows athletes to complete more repetitions per set and recover faster between sets. Consequently, creatine supplementation has gained increasing popularity, particularly among athletes and physically active individuals. Additionally, creatine's influence on muscle protein synthesis is also linked to its ability to improve muscle cell hydration [15]. Aim of the Study: The aim of this study is to evaluate the impact of creatine supplementation on physical performance and muscle recovery, as well as to review its efficacy, safety, and potential side effects. Material and Methods: A review and analysis of randomized clinical trials and clinical studies from 2010 to 2025 available in PubMed and Google Scholar. Conclusions: Research findings indicate that long-term creatine use does not cause significant adverse side effects. Individuals supplementing with creatine have shown an increase in lean body mass without any undesirable effects on liver and kidney function. By improving muscle strength and endurance, creatine helps stabilize joints, thereby reducing the risk of musculoskeletal injuries [13]. From a practical perspective, these findings provide valuable insights for athletes, coaches, and physically active individuals striving to enhance both short-term and long-term training outcomes through creatine supplementation.

30 May 2026 in Quality in Sport
Verified
Journal Article
Open access
AMAleksandra Malcher
Aleksandra Malcher
ZKZuzanna Zofia Kamińska
Zuzanna Zofia Kamińska
AZAgnieszka Zielińska
Agnieszka Zielińska
IZIgor Zydlewski
Igor Zydlewski
AJAleksandra Jakimowicz
Aleksandra Jakimowicz
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
Background. Women's participation in sport has grown substantially, yet female athletes remain underrepresented in sport science research, with much of the existing evidence derived from male populations. Fluctuations of estrogen and progesterone across the menstrual cycle, together with widespread use of hormonal contraceptives, are increasingly recognised as factors that may influence athletic outcomes. Aim. To synthesise current evidence on the effects of female reproductive hormones on athletic performance, injury risk, and recovery, and to translate it into practical, individualised recommendations for coaches, practitioners, and athletes. Methods. PubMed was searched for systematic reviews, meta-analyses, and original studies on the menstrual cycle, hormonal contraceptives, and athletic outcomes. Results. Group-level effects of menstrual cycle phase on objective performance outcomes such as strength, power, and endurance are generally small and inconsistent. Evidence linking cycle phase to anterior cruciate ligament injury risk is suggestive but limited by methodological heterogeneity, whereas hormonal contraceptive use does not appear to be protective against musculoskeletal injuries. Outcomes related to recovery appear more sensitive to hormonal context than objective performance measures, with recent evidence converging on menstrual symptom burden as a predictor of disturbed recovery in female athletes. Conclusions. Female reproductive hormones influence multiple physiological systems relevant to sport, but their effects on athletic outcomes are predominantly individual rather than uniform. The strongest evidence-based approach for supporting female athletes combines individualised, symptom-led monitoring with established principles of training periodisation, injury prevention, and athlete education. Progress in this field will depend on longitudinal research with biochemical phase verification and a focus on individual response patterns.

7 May 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
MMMartyna Mrozek
Martyna Mrozek
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
ZKZuzanna Zofia Kamińska
Zuzanna Zofia Kamińska
AZAgnieszka Zielińska
Agnieszka Zielińska
IZIgor Zydlewski
Igor Zydlewski
AMAleksandra Malcher
Aleksandra Malcher
PROM and its preterm form, pPROM, are major contributors to preterm birth and remain closely associated with serious maternal and neonatal complications. Growing evidence suggests that disruption of vaginal microbial homeostasis mayis closely linked to the pathogenesis of pPROM. In particular, the loss of protective Lactobacillus crispatus, accompanied by a shift toward Lactobacillus iners, anaerobic bacteria, and increased microbial diversity, appears to destabilize the vaginal ecosystem, promote local inflammation, activate matrix metalloproteinases, and ultimately compromise the structural integrity of the fetal membranes. Current empirical antibiotic therapy for pPROM does not account for interindividual variability in the vaginal microbiota and may paradoxically aggravate dysbiosis. In response to these limitations, emerging therapeutic strategies are increasingly focused on microbiota-targeted interventions, including personalized probiotic therapies, immunological and biological approaches, and vaginal microbiota transplantation. In addition, specific microbial signatures may serve as potential biomarkers of pPROM, thereby opening new avenues for personalized prevention and treatment. Although further prospective studies are required to validate the safety and efficacy of these emerging therapies, their potential already represents a promising direction for the future of modern perinatal medicine.